8-K

                                UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C.  20549

                                 Form 8-K

                              Current Report
       Pursuant to Section 13 or 15(d) of the Securities Act of 1934

  Date of Report (Date of earliest event reported)     December 7, 2009
                    --------------------------

                   Dynasil Corporation of America
     ------------------------------------------------------------
    (Exact name of registrant as specified in its charter)

       Delaware                     000-27503         22- 1734088
  ---------------------------       ----------        -----------
  (State or other                   (Commission     (IRS Employer
  jurisdiction of incorporation)    File Number) Identification No.)


              385 Cooper Road, West Berlin, New Jersey 08091
      ------------------------------------------------------------
           (Address of principal executive offices)   (ZIP Code)

  Registrant's telephone number, including area code:  (856)-767-4600

                             Not Applicable
    ------------------------------------------------------------
       (Former name or former address, if changed since last report)

  Check the appropriate box below if the Form 8-K filing is
  intended to simultaneously satisfy the filing obligation of
  the registrant under any of the following provisions (see
  General Instructions A.2. below):

  [] Written communications pursuant to Rule 425 under the
  Securities Act (17 CFR 230.425)

  [] Soliciting material pursuant to Rule 14a-12 under the
  Exchange Act (17 CFR 240.14a-12)

  [] Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))

  [] Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))

  Section 8 - Other Events

  


  Item 8.01 Other Events.

       On December 7, 2009, the Registrant, Dynasil Corporation of
  America ("Dynasil"), issued a press release announcing that the nominees
  for director at Dynasil's Annual Meeting on February 3, 2010 would
  include Dynasil's current five directors and Dr. Michael Joyner of the
  Mayo Clinic and Mr. David Kronfeld of JK&B Capital.  The information set
  forth in that press release, which is filed as an exhibit to this
  Report, is incorporated herein by reference.


  Section 9 - Financial Statements and Exhibits

  Item 9.01. Financial Statements and Exhibits.

  EXHIBIT INDEX

  (c)  Exhibits

  99.1 Dynasil Corporation of America press release dated December 7, 2009

  

                           SIGNATURES

       Pursuant to the requirements of the Securities Exchange Act of
  1934, the registrant has duly caused this report to be signed on its
  behalf by the undersigned hereunto duly authorized.

                           DYNASIL CORPORATION OF AMERICA
                                     (Registrant)

  Date:                         By   Craig T. Dunham
                                     President

EX-99

                                   Contact:  Patty Kehe
                                   Dynasil Corporation of America
                                   Phone: (607) 272-3320, ext. 26
                                   Email:  pkehe@DynasilCorp.com

  Dynasil Announces the Nominations of Dr. Michael Joyner of the Mayo
  Clinic and Mr. David Kronfeld of JK & B Capital as New Directors

  WEST BERLIN, N.J.   December 7, 2009 - Dynasil Corporation of America
  (OTCBB: DYSL.OB), a rapidly growing manufacturer of specialized
  instruments, detectors and products with applications in homeland
  security/defense, cancer detection, medical and industrial, today
  announced that Dr. Michael Joyner of the Mayo Clinic and Mr. David
  Kronfeld of JK&B Capital of Chicago have been nominated for election to
  the Dynasil Board of Directors at its February 3, 2010 Annual Meeting.
  Dynasil Chairman, Peter Sulick said, "It is with great pride and
  enthusiasm that I look forward to welcoming these distinguished
  individuals to our Board.  Dynasil's 2008 acquisition of RMD Inc.
  brought a host of new intellectual property ripe for commercialization
  into the Company. These assets represent exciting new opportunities in
  advanced scintillator design, micro crack detection, dosimeter,
  photodiode design, and a number of other important growth areas for the
  21st century. Dr. Joyner and Mr. Kronfeld will bring very specific and
  unique skill sets to the Dynasil Board.  We expect that their
  participation will help guide the Company through the decision-making
  process for the commercialization of this Intellectual Property into
  successful business opportunities. They also bring a view of the future
  which will help focus Dynasil's extensive and deep research capability
  towards areas of future growth. Their involvement will elevate Dynasil's
  potential substantially."

  Michael J. Joyner, M.D. serves as the Associate Dean for research at
  Mayo Clinic in Rochester, Minnesota where he also is Deputy Director for
  Research, associate program director of the Center of Translational
  Science Activities and a consultant to the Department of Anesthesiology.
  He also holds the prestigious Frank R. and Shari Caywood Professorship.
  He received his undergraduate and medical degrees from the University of
  Arizona.  Dr. Joyner's work has been funded continuously by NIH since
  the early 1990s. He has held important editorial positions for key
  journals, served as an NIH study section member, and received numerous
  national and international awards for his work on muscle blood flow and
  human physiology. A number of Dr. Joyner's former fellows now direct
  independent research programs in the US, Canada, Europe and Japan.

  Mr. Kronfeld founded JK&B Capital, a venture capital firm focused in the
  software, IT and communications markets with over $1.1 billion of
  cumulative capital under management. Mr. Kronfeld is an experienced
  venture capital investor and telecommunications industry executive with
  over 30 years of experience. Prior to forming JK&B, Mr. Kronfeld was a
  General Partner at Boston Capital Ventures (BCV) where he focused on
  making venture capital investments in telecommunications and software
  companies. Before joining BCV, Mr. Kronfeld was Vice President of
  Acquisitions and Venture Investments with Ameritech where he was
  responsible for directing its venture capital investments in a broad
  array of telecommunications-related companies and all of Ameritech's
  mergers and acquisitions activities.  In addition, Mr. Kronfeld was a
  Senior Manager at Booz Allen & Hamilton and a Systems Analyst at
  Electronic Data Systems (  Mr. Kronfeld earned a Bachelor of Science in
  Electrical Engineering with high honors, a Master of Science in Computer
  Science from Stevens Institute of Technology, and a Master of Business
  Administration from The Wharton School of Business.  He has been a
  director of four public and over thirty private company boards.

  Craig Dunham, Dynasil CEO added, "While we are justifiably proud of the
  Company's 645% growth over the past five years and the returns we've
  given our shareholders, we are always looking to the future and what
  steps we can take to maintain this course. By adding the substantial
  talent and creativity of Dr. Joyner and Mr. Kronfeld to our Board, we
  will be taking one of those steps. I'm eager to begin working with them
  and continuing to grow Dynasil."

  About Dynasil

  Dynasil is a rapidly growing manufacturer of specialized instruments and
  products for a broad range of applications markets in the homeland
  security/defense, medical and general industrial sectors.  In addition,
  the Company is engaged in a significant amount of contract research for
  the government and private industry.  Dynasil and its subsidiaries have
  operations in New Jersey, New York and Massachusetts.

  This news release may contain forward-looking statements usually
  containing the words "believe," "expect," "plan," "target," "intend" or
  similar expressions.  These statements are made pursuant to the safe
  harbor provisions of the Private Securities Litigation Reform Act.
  Future results of operations projections, and expectations, which may
  relate to this release, involve certain risks and uncertainties that
  could cause actual results to differ materially from the forward-looking
  statements.  Factors that would cause or contribute to such differences
  include, but are not limited to, the factors detailed in the Company's
  Annual Report or Form 10-KSB and in the Company's other Securities and
  Exchange Commission filings, continuation of existing market conditions
  and demand for our products.